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STAT3 (ser727)The purpose of this study was to identify the role of phospholipase D (PLD) isozymes in Bcl-2 expression.
Overexpression of PLD1 or PLD2 increased Bcl-2 expression and phosphatidic acid (PA), the product of
PLDs, also upregulated Bcl-2 expression. Treatment with PA activated the phospholipase A2 (PLA2)/Gi/
ERK1/2, RhoA/Rho-associated kinase (ROCK)/p38 MAPK, and Rac1/p38 MAPK pathways. PA-induced phos-
phorylation of ERK1/2 was attenuated by a PLA2 inhibitor (mepacrine) and, a Gi protein inhibitor (pertussis
toxin, PTX). On the other hand, p38 MAPK phosphorylation was attenuated by a dominant negative Rac1 and
a speciﬁc Rho-kinase inhibitor (Y-27632). These results suggest that PLA2/Gi acts at the upstream of ERK1/2,
while Rac1 and RhoA/ROCK act upstream of p38 MAPK. We next, tried to determine which transcription
factor is involved in PLD-related Bcl-2 expression. When signal transducer and activator of transcription 3
(STAT3) activity was blocked by a STAT3 speciﬁc siRNA, PA-induced Bcl-2 expression was remarkably
decreased, suggesting that STAT3 is an essential transcription factor linking PLD to Bcl-2 upregulation. Taken
together, these ﬁndings indicate that PLD acts as an important regulator in Bcl-2 expression by activating
STAT3 involving the phosphorylation of Ser727 through the PLA2/Gi/ERK1/2, RhoA/ROCK/p38 MAPK, and
Rac1/p38 MAPK pathways.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The proto-oncogene, Bcl-2, was originally identiﬁed at the chro-
mosomal breakpoint in t (14;18) bearing follicular B cell lymphoma
[1]. Bcl-2 is a 26 kDa membrane-bound protein that is present in
several subcellular locations including the outer mitochondrial, outer
nuclear, and endoplasmic reticulum membranes [2,3]. Bcl-2 family
members that favor cell death include those containing multiple BH
domains (Bax, Bak and Bok), and those that contain only the BH3
sequence (Bad, Bik, Bid, Bmf, Nova and Hrk). Anti-apoptotic Bcl-2
proteins are, Bcl-2, as well as Bcl-xL, Mcl-1, A1 and Bcl-w [4]. Bcl-2
can protect a variety of cell types against stress-induced apoptosis,
and it controls outer mitochondrial membrane permeability and the
release of cytochrome C [5–7]. It is also reported to be involved in regu-
lation of the cell cycle, cell differentiation, and gene expression [8–10].ic acid; Bcl-2, B-cell leukemia/
dic acid; DPPA, 1,2-dipalmitoyl-
ein kinase; ERK, extracellular
CR, G protein-coupled receptor;
DN, dominant negative; siRNA,
ding domain
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viously reported that PLD can regulate Bcl-2 expression in stomach
cancer cells [11] and that overexpression of PLD2 enables A20 murine
B lymphoma cells to resist Fas-induced apoptosis by increasing Bcl-2
and Bcl-xL expression [12].
Phospholipase D (PLD), a phospholipids phosphohydrolase, cata-
lyzes the hydrolysis of phosphatidylcholine to phosphatidic acid (PA)
and choline. While the generation of choline by PLD may have some
second messenger functions, it is widely believed that PA is the most
critical metabolite generated by PLD. PA can also be metabolically
converted to diacylglycerol (DAG) and lyso-PA (LPA), both of which
have second messenger roles that could contribute to the effects of
PLD. PLD has two isoforms, PLD1 and PLD2, with signiﬁcant differences
in their regulation and subcellular distributions. PLD1 is present
throughout the cell, particularly in Golgi, perinuclear, and heavy
membrane fractions, in contrast PLD2 is localized almost exclusively
in the plasma membrane of the light membrane “lipid raft” which co-
fractionates with caveolin [13]. PLD1 is activated by ARF-, Ral-, and
Rho-family GTPases, and PKCα while PLD2 activity is elevated by fatty
acids, but is unaffected byGTPases or PKCα [14]. PLDplays an important
regulatory role in various cellular processes, including cell migration,
receptor endocytosis, exocytosis, cytoskeletal reorganization andmem-
brane trafﬁcking [14], cell proliferation [15], the immune response [16],
differentiation, survival, and apoptosis [17]. Although PLDs act as im-
portant regulators in the signaling pathways involved in cell survival,
the role of PLDs in these pathways is still not fully understood.
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Rac1, play an important role in cellular functions including the cell
cycle, cell polarity, survival, and migration [18]. The GTP-binding
form of Rho can interact with their speciﬁc effecters and activate a
range of downstream targets. In particular, Rho and its downstream
effectors, such as Rho-associated kinase (Rho kinase) are involved in
reorganization of the actin cytoskeleton in processes such as smooth
muscle constriction [19]. Rho GTPases control the activity of phospho-
lipase D (PLD) [20] and Rho-kinase most likely functions upstream
of p38 mitogen activated protein kinase (MAPK) and stress-activated
protein kinase/c-jun N-terminal kinase (SAPK/JNK) in osteoblasts
and acts as a positive regulator [21]. Among the Rho family members,
Rac1, a key component of cell movement and cell spreading, is crucial
for generating actin-rich lamellipodial protrusions [22]. Rac1 executes
its biological functions by activating downstream effectors, one of
the best characterized of these being p21-activated kinase (PAK). It
has been reported that Rac1 can activate p38 MAPK [23] as well as
extracellular-regulated protein (ERK1/2) [24].
One of the relevant downstream signaling cascades for mitogenic
PLD signaling is theMAPK pathway, which includes theMAPK family's
ERK1/2, p38 MAPK and SAPK/JNK. The signals that activate the MAPK
pathways in response to PLD signal have been identiﬁed [25,26]. Re-
cently it has been reported that ERK1/2 induces the expression of
Bcl-2 and Bcl-xL, and promotes the survival of human pancreatic
tumor cells [27]. In addition, several MAPK family members including
ERK1/2, p38 MAPK, and JNK are as kinases can phosphorylate Ser727
of the signal transducer and activator of transcription 3 (STAT3)
[28–30]. STAT3 is responsible for the expression of several cytokines
and growth factor receptors and is activated by phosphorylation at
Tyr705, which induces its dimerization, nuclear translocation and
DNA binding. In addition, activation of STAT3 results in the upregula-
tion of various genes involved in the cell survival and proliferation
such as Bcl-2, Bcl-xL, Mcl-1, cyclin D, and c-Myc.
In this study, we investigated the role of PLD in the Bcl-2 expres-
sion in HeLa cells. We found that PLD was important for upregula-
tion of Bcl-2 and PA, an end product of PLD action also stimulated
the expression of Bcl-2. Regulation of Bcl-2 expression occurred
though three different pathways: the PLA2/Gi/ERK1/2, RhoA/ROCK/
p38 MAPK and Rac1/p38 MAPK pathways. We also obtained evidence
that STAT3 (Ser727) is a key transcription factor for the induction
of Bcl-2 by PLD. Collectively, these observations suggest that PLD
plays a critical role in enhancing Bcl-2 expression though PLA2/Gi/
ERK1/2, RhoA/ROCK/p38 MAPK, and Rac1/p38 MAPK pathways in
HeLa cells.
2. Materials and methods
2.1. Materials
Fetal bovine serum (FBS), penicillin/streptomycin solution, and
Dulbecco's modiﬁed Eagle's medium (DMEM) with L-glutamine
and high glucose were purchased from WelGENE (Daegu, Korea).
1,2-Dipalmitoyl-sn-glycero-3-phosphate (DPPA), 1,2-Dioctanoly-sn-
glycerol-3-phosphate sodium salt (PA) and oleoyl-sn-glycero- 3-
phosphate (LPA) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Antibodies used were as follows: Bcl-2 monoclonal anti-
body and GAPDH polyclonal antibody were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). PLD1 polyclonal antibody,
ERK1/2 polyclonal antibody, p-ERK1/2 monoclonal antibody, p38
MAPK polyclonal antibody, p-p38 MAPK polyclonal antibody,
STAT3 polyclonal antibody and p-STAT3 (Ser727) polyclonal antibody
were obtained from Cell signaling (Beverly, MA, USA). Rac and Rho ac-
tivation kits were from Upstate Biotechnology, Inc (Temecula, CA).
Propranolol and mepacrine were purchased from Sigma-Aldrich (St.
Louis, MO, USA). PD98059, SB203580, and Y-27632 were obtained
from Calbiochem (San Diego, CA, USA).2.2. Cell culture
HeLa cells were incubated for 2 days at 37 °C in Dulbecco's modi-
ﬁed Eagle's medium (DMEM) supplemented with 10% (v/v) heat-
inactivated FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin.
Cells were grown at 37 °C in a humidiﬁed CO2-controlled (5%) incuba-
tor, then washed with DMEM containing 0.1% (w/v) bovine serum
albumin, 100 U/ml penicillin, and 100 μg/ml streptomycin (serum-
free medium) and incubated in serum-free medium at 37 °C for 18 h
before treatment.
2.3. Transient transfection and infection of HeLa cells
For transient infection, retroviral constructs of vector-control, PLD1
wild type (wt), and PLD2 wild type (wt) were added to HeLa cells.
After overnight culture, the virus containing medium was replaced
with fresh complete medium.
For transfection experiments, 5 μg each of Cdc42 dominant-negative
(N17), RhoA dominant-negative (N19), Rac1dominant-negative (N17),
pMSCV-HA-IRES-CL-EGFP and pMSCV-HA-STAT3-IRES-CL-EGFP plas-
mid were transiently transfected into HeLa cells, using Lipofectamine™
2000 reagents (Invitrogen, CA, USA). After 48 h of transfection, the cells
were serum-starved for 18 h and then treated with PA.
2.4. Western blot analysis
Cells were ﬁrst lysed in 20 mM Tris, pH 7.5, containing 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate,
1% Triton X-100, 1 mM phenylmethylsulfonyl-ﬂuoride, and 1 mM
Na3VO4. Protein lysates ranging from 20 to 30 μg were subsequently
loaded onto SDS-polyacrylamide gels (10–12%), electrophoresed,
and transferred to nitrocellulose membrane (Amersham Biosciences).
After being blocked with 5% dried skim milk for 1 h, the membrane
was incubated with primary antibodies. Blots were further incubated
with horseradish peroxidase-conjugated secondary antibody (1:2000,
New England Biolabs, Beverly, MA), and speciﬁc bands were detected
with ECL (Ab FRONTIER).
2.5. Luciferase assay
The Bcl-2 promoter construct was provided by Gu Kong (Hanyang
University, Seoul, Korea). Cells were cotransfected with either the
control vector (pCAT-Luc) and pCMV-β-gal or Bcl-2 promoter (Bcl-2
pCAT-Luc) and pCMV-β-gal with PLD1and PLD2. At 48 h after the
transfection, cells were stimulated with PA for 3 h. Depending on the
reporter construct used the level of expression from the target was
analyzed by Fireﬂy luciferase assay. Luciferase activities, read with
a Luminometer (Berthold, USA) were normalized to β-galactosidase
activity measured in the corresponding cell extracts.
2.6. Chromatin immunoprecipitation (CHIP) assay
Nuclear isolation, cross-linking, and chromatin immunoprecipita-
tion assays (CHIP) on PA-stimulated HeLa cells were performed as
described previously [31]. Precipitated DNA fragments were analyzed
by PCR using primers against relevant human Bcl-2 promoters.
Primers used were as follows: STAT3 (1), sense, 5′-CTTCATTTATC-
CAGCAGCTT-3′ and antisense, 5′-GAGGGGACGATGAAGGAG-3′, PCR
conditions comprised an initial polymerase activation step at 94 °C
for 5 min, followed by denaturation for 33 cycles at 94 °C for 30 s,
annealing at 56 °C for 30 s and extension at 72 °C for 30 s. For STAT3
(2), sense,5′-CTCTTGAGATCTCCGGT-TG-3′ and antisense, 5′-GGGGA-
GAGGGA-GTAAAAAT-3′. The PCR conditions comprised an initial poly-
merase activation step at 94 °C for 5 min, followed by denaturation for
28 cycles at 94 °C for 30 s, annealing at 56 °C for 30 s and extension at
72 °C for 30 s.
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For pull down assays, HeLa cells were lysed in 125 mM HEPES, pH
7.5, containing 750 mM NaCl, 5 mM EDTA, 5% lgepal CA-630, 50 mM
MgCl2, 10% glycerol 10 μg/ml aprotinine and 10 μg/ml leupeptin.
Equal amounts of total protein from clariﬁed lysates were incubated
with GST-PBD (p21-binding domain of human PAK-1) or GST-RBD
(Rho binding domain of rhotekin) to precipitate GTP-bound Rac1 and
GTP-bound RhoA, respectively, according to themanufacturer's instruc-
tions (Upstate Biotechnology). Precipitated GTP-bound Rac1 and RhoA
were resolved by a 12% SDS-PAGE and immunoblotted with monoclo-
nal antibodies speciﬁc for Rac1 (1 μg/ml; Upstate Biotechnology) or
RhoA (3 μg/ml; Upstate-Biotechnology). Six percent of each cell lysate
was also resolved by 12% SDS-PAGE and immunoblotted to measure
the total amounts of Rac1 and RhoA.
2.8. Small interfering RNA
Human STAT3 siRNA was purchased from Ambion (Austin, TX,
USA), and Human RhoA and Rac1 were purchased from Bioneer
(Seoul, Korea). A negative control was carried out with Negative
Control siRNA #2 (from Ambion). The oligonucleotide siRNAs were
transfected using siPORTTM NeoFX (Ambion) reagent according to
the manufacturer's instructions. At the indicated intervals following
transfection, cell lysates were assayed for gene silencing by Western
blotting.
2.9. Statistical analysis
All experiments were performed at least in triplicate, and results
are expressed as means±SD. The statistical signiﬁcance of differences
was assessed by an unpaired t-test.
3. Results
3.1. PLD overexpression increases Bcl-2 expression in HeLa cells
To investigate the role of PLD in the Bcl-2 expression in HeLa cells,
we ﬁrst tested whether Bcl-2 expression was stimulated by infectionFig. 1.Overexpression of either PLD1 or PLD2 inHeLa cells increases Bcl-2 expression. (A) HeLa
At 72 h after infection, cell lysates were analyzed by Western blot analysis using PLD1, PLD2
HeLa cells along with 5 μg of pCMV-β-gal and wt PLD isozyme constructs and luciferase assay
are representative of triplicate experiments. (C) Expression of Bcl-2 in the cells was examined
analyzed by 12% SDS-PAGE and subsequent Western blotting with anti-Bcl-2 antibody. (D) Ce
gal, and then treated with 50 μM PA for 3 h. The results are representative of triplicate experimof vectors containing wild-type PLD1 or PLD2. Overexpression of the
PLD isozymes indeed enhanced the expression of Bcl-2 as well as
the activity of its promoter (Fig. 1A and B). Moreover, PA, the end
product of PLD, increased expression of Bcl-2 (Fig. 1C). As shown in
Fig. 1D, PA also signiﬁcantly increased Bcl-2 promoter activity
(pb0.01). These results indicate that PLD plays an essential role in
the expression of Bcl-2 in HeLa cells.
3.2. PA is involved in upregulation of Bcl-2 expression in HeLa cells
In general, PLD exerts its effects by generating PA. PA is degraded to
diacylglycerol by phospholyhydrolase (PAP) or to LPA/arachidonic acid
(AA) by PLA2. Therefore, to determine whether PA itself regulates Bcl-2
expression, we pretreated cells with mepacrine (a PLA2 inhibitor) or
propranolol (a PAP inhibitor) for 1 h prior to treatment with PA for
3 h. As shown in Fig. 2A, pretreatment with mepacrine reduced PA-
induced Bcl-2 expression, whereas pretreatment with propranolol
had no effect on Bcl-2 expression, suggesting that a PLA2 metabolite of
PA is involved in the expression of Bcl-2. PLA2 converts PA into AA
and LPA. To conﬁrm which of PA metabolites are involved in the
increased Bcl-2 expression, we treated DPPA which contains palmitic
acid instead of AA, for 1 h. Treatment with DPPA resulted in increased
Bcl-2 expression (Fig. 2B). Moreover, when the cells were treated
with LPA for the indicated time, Bcl-2 expression was also increased
(Fig. 2C). These results suggest that LPA, as a metabolite of PA by PLA2
has great importance in the upregulation of Bcl-2.
3.3. The PLA2/Gi/ERK1/2, RhoA/ROCK/p38 MAPK, and Rac1/p38 MAPK
pathways are involved in expression of Bcl-2 by PLD in HeLa cells
PLD activates the MAPK cascade through PA-mediated transloca-
tion of Raf-1 to cellular membranes [26]. In addition, MAP kinase is
a well-known target of PA. To investigate whether the MAP kinase
cascade is involved in PLD-mediated signaling events, we infected
HeLa cells with vector control, and vector expressing wild-type
PLD1 or wild-type PLD2. As, shown Fig. 3A, overexpression of PLD1
or PLD2, increased activation of ERK1/2. Treatment with PA also in-
creased ERK1/2 phosphorylation with a maximum effect after 15 min
(Fig. 3B). In addition, to determine whether PLA2 is involved in thecells were infectedwith control retroviral vector and vectors harboringwtPLD1 orwtPLD2.
and Bcl-2 antibodies. (B) A Bcl-2 promoter–luciferase construct was cotransfected into
s were performed on cell lysates using a Luminometer (Berthold, MA, USA). The results
after PA (50 μM) treatment for 3 h. Samples of extracts containing 25 μg of protein were
lls were cotransfected with the Bcl-2 promoter–luciferase construct and 5 μg of pCMV-β-
ents.
Fig. 2. Effect of PA on Bcl-2 expression in HeLa cells. (A) Cells were pretreated with mepacrine (50 μM) or propranolol (50 μM) for 30 min and then stimulated with 50 μM PA
for 3 h. The expression level of Bcl-2 was determined by Western blot analysis. (B) Cells were incubated for 1 h with 5 or 10 μM DPPA after 18 h serum-starvation. The cells
were harvested, lysed and subjected to Western blot analysis for Bcl-2 and GAPDH. (C) Cells were stimulated with LPA (10 μM) for the indicated time periods. Expression of
Bcl-2 was determined by Western blot analysis. Band intensities were quantiﬁed using Image J software (NIH—http//rsb.info.nih.gov/ij/).
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inhibitor, mepacrine. Pretreatment with mepacrine suppressed PA-
induced ERK1/2 activation (Fig. 3C), indicating that ERK1/2 function at
the downstream of PLA2.
LPA has been described as a PLD activator in several different cells
types, including ﬁbroblasts, endothelial cells, epithelial cells, and
prostate cancer cells [32–36]. It is coupled to a variety of downstream
signaling cascades through different classes of G proteins including
Gi, Gq, and G12/13 [37]. It induces various biological effects throughFig. 3. PLA2, Gi, and ERK1/2 are involved in PLD-mediated Bcl-2 expression in HeLa cells. (A
and wtPLD2. At 72 h after infection, the cells were lysed and levels of ERK1/2 and p-ERK1/2
for the indicated time periods and levels of ERK1/2 and p-ERK1/2 were again determined byW
then stimulated with PA (50 μM) for 15 min and levels of ERK1/2 and p-ERK1/2 were determ
and stimulated with 10 μM LPA for 15 min (for p-ERK1/2) and 3 h (for Bcl-2). Levels of ERK1
were quantiﬁed as before.both pertussis toxin (PTX)-sensitive (Gi) and -insensitive (G12/13,
Gq) G-proteins. Moreover, MAPKs, including ERK1/2, and p38 MAPK,
have been shown to be activated downstream of GPCR. As shown in
Fig. 3D, LPA-induced ERK1/2 phosphorylation and Bcl-2 expression
were inhibited by treatment with PTX, which demonstrates that acti-
vation of ERK1/2 and upregulation of Bcl-2 expression by LPA are
mediated through Gi-protein activation. Therefore, we further ex-
amined whether another MAPKs, p38 MAPK, is also involved in
PLD-mediating signaling in HeLa cells. To conﬁrm the activation of) HeLa cells were infected with control retroviral vector and vectors harboring wtPLD1
were determined by Western blot analysis. (B) Cells were stimulated with PA (50 μM)
estern blot analysis. (C) Cells were pretreated with mepacrine (50 μM) for 30 min and
ined byWestern blot analysis. (D) Cells were pretreated with PTX (400 ng/ml) for 24 h
/2, p-ERK1/2, and Bcl-2 were determined by Western blot analysis and band intensities
Fig. 4. Activations of p38 MAPK, RhoA/ROCK, and Rac1 are involved PLD-mediated Bcl-2 expression in HeLa cells. (A) HeLa cells were infected with control retroviral vector and
vectors harboring wtPLD1 and wtPLD2. Three days later they were lysed. Phosphorylation of p38 MAPK was determined by Western blot analysis. (B) Cells were stimulated
with PA (50 μM) for the indicated time periods and expression of p38 MAPK and p-p38 MAPK was determined by Western blot analysis. (C) Cells were pretreated with mepacrine
(50 μM) for 30 min and then stimulated with PA (50 μM) for 15 min. Expression level of p38MAPK and p-p38MAPK was determined by Western blot analysis. (D) Cells were
stimulated with LPA (10 μM) and expression of p38 MAPK and p-p38 MAPK was determined by Western blot analysis. (E) Cells were transfected with 5 μg of either vector
control or vectors expressing dominant-negative forms of Cdc42 (N17), RhoA (N19), or Rac1 (N17), using lipofectamin 2000 reagent. At 48 h later the cells were treated with
50 μM PA for 15 min (for p38 MAPK) and 3 h (for Bcl-2), and p38MAPK, p-p38MAPK and Bcl-2 were assayed by Western blot analysis. (F) HeLa cells were transiently transfected
with 100 nM RhoA, Rac1 siRNA,respectively, and scrambled siRNA as a control for 48 h and then stimulated with 50 μM PA for 15 min (for RhoA, Rac1 and p- p38MAPK) and 3 h
(for Bcl-2). Expression levels of RhoA, Rac1, p38MAPK, p-p38MAPK, and Bcl-2 were determined by Western blot analysis. (G) After serum starvation, cells were treated with
PA for 15 min. Activated RhoA (upper panel) and Rac1 were determined as described in Section 2 by measurement of their GTP-bound form. (H) After serum starvation, cells
were treated with LPA for 15 min. Activated RhoA (upper panel) and Rac1 were determined as described in Section 2 by measurement of their GTP-bound form. (I) Cells
were pretreated with Y-27632 (10 μM) for 1 h and then stimulated with 50 μM PA for 15 min (for p-p38 MAPK) and 3 h (for Bcl-2). Expression of p38MAPK, p-p38MAPK
and Bcl-2 were determined by Western blot analysis. Bands intensities were using Image J software (NIH—http//rsb.info.nih.gov/ij/).
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Activation of p38 MAPK was increased by overexpression of PLD or
treatment of PA in a time dependent manner (Fig. 4A and B). Next,
to ﬁnd out whether PLA2 is involved in the PA-induced p38 MAPK ac-
tivation, effect of mepacrine, the PLA2 inhibitor, was measured. This
did not affect PA-induced p38 MAPK phosphorylation (Fig. 4C). To
conﬁrm LPA is not required for the PA-induced p38 MAPK activation,
we treated LPA for 15 min to the cells. Treatment with LPA has no
effect on p38 MAPK activation (Fig. 4D). These results indicate that
PLA2/Gi pathway is not involved in the PA-induced p38 MAPK phos-
phorylation. Small GTP-binding proteins including Rho, Cdc42, and,
Rac1 have been implicated in cellular responses such as apoptosis,
migration, proliferation, and gene expression. The MAPKs including
ERK1/2, p38 MAPK, and SAPK/JNK act downstream of these small
GTP-binding proteins [38]. In addition, activation of Rho can prevent
apoptosis by increasing expression of the Bcl-2 and Bcl-xL [39,40]. To
investigate possible roles of Cdc42, RhoA, and Rac1 in PLD-mediated
Bcl-2 expression, we transfected HeLa cells with dominant-negative
mutants of each of these factors and then the cells were treated with
PA for 3 h. As shown Fig. 4E, PA-induced increase of p38 MAPK phos-
phorylation and Bcl-2 expression were reduced in cells transfected
with dominant-negative mutants of RhoA and Rac1, but not that
of Cdc42. However, ERK1/2 phosphorylation was unaffected by any
of the dominant negative small GTP-binding proteins (data not
shown). Also, we conﬁrmed the effect of RhoA and Rac1 on Bcl-2 ex-
pression by introducing RhoA and Rac1 speciﬁc siRNAs. PA-induced
increase of p38 MAPK phosphorylation and Bcl-2 expression were
completely abolished with treatment of RhoA and Rac1 siRNAs
(Fig. 4F). These ﬁndings demonstrated that RhoA and Rac1 are re-
quired for both of the activation of p38 MAPK and Bcl-2 expression.
To assess the effect of PA on activations of RhoA and Rac1, we mea-
sured the intracellular concentrations of GTP-bound RhoA and Rac1
in the presence or absence of PA and LPA, as described in Section 2.
PA increased the GTP-bound forms of both factors, but LPA did
not (Fig. 4G and H). To determine whether the Rho-kinase, ROCK, a
downstream target of Rho, was involved in the PA-induced increase
of p38 MAPK phosphorylation and Bcl-2 expression, we treated cells
for 1 h with Y27632, a speciﬁc inhibitor of Rho-kinase and found
that Y27632 reduced p38MAPKphosphorylation and Bcl-2 expression
induced by PA treatment (Fig. 4I). Taken together, these results
suggest that PA activates RhoA and Rac1, which may in turn enhance
of Bcl-2 expression via a p38 MAPK-mediated pathway.
3.4. PA-induced Bcl-2 expression is dependent on the activation of ERK1/2
and p38 MAPK in HeLa cells
As shown in Figs. 3 and 4, ERK1/2 and p38 MAPK are activated by
overexpression of PLD isozymes in HeLa cells. As expected, the levelFig. 5. Activations of the ERK1/2 and p38 MAPK are involved in PA-induced Bcl-2 expression
for 1 h and then stimulated with 50 μM PA for 15 min (for p-ERK1/2, p-p38 MAPK) and 3 h
were determined by Western blot analysis. Bands were quantiﬁed using Image J software (of phosphorylated ERK1/2 and p38 MAPK was increased after treat-
ment of PA. To determine whether ERK1/2 and p38MAPK are actually
involved in the Bcl-2 expression induced by PA, we used the MEK
inhibitor, PD98059 and p38MAPK inhibitor, SB203580, to block acti-
vation of ERK1/2 and p38MAPK, respectively. As shown in Fig. 5,
when the cells were pretreated with either PD98059 or SB203580,
PA-induced Bcl-2 expression was reduced, but not completely. When
the cells were pretreated with both PD98059 and SB203580 at the
same time, PA-induced Bcl-2 expression was completely blocked,
demonstrating that PA independently induces Bcl-2 expression through
both the ERK1/2 and P38 MAPK pathways.
3.5. The activation of STAT3 is involved in Bcl-2 expression by PLD in
HeLa cells
STAT3 is a key signaling molecule for many cytokines, and it is acti-
vated by phosphorylation of Ser 727 and/or Tyr 705 residues which are
targets of MAPKs [41,42]. Therefore, we examined STAT3 phosphoryla-
tion after infection with constructs expressing the PLD isozymes. Over-
expression of PLD isozymes increased Ser727 phosphorylation of STAT3
(Fig. 6A). PA, also increased STAT3 (Ser 727) phosphorylation in a time-
dependent manner (Fig. 6B). Phosphorylation of Tyr705 residue of
STAT3 was not affected by overexpression of PLD isozymes or PA treat-
ment (data not shown). PA-induced STAT3 (Ser 727) phosphorylation
was inhibited by pretreatment with mepacrine or PTX (Fig. 6C and D),
as well as by transfection with the dominant-negative mutants of
RhoA or Rac1 (data not shown). As shown in Fig. 6E, PD98059 and
SB203580 partially blocked PA-induced STAT3 (Ser727) phosphoryla-
tion, respectively, whereas treatment with both of PD98059 and SB
203580 at the same time completely blocked PA-induced STAT3 phos-
phorylation, indicating that PA-induced STAT3 phosphorylation occurs
through ERK1/2 and p38MAPKpathways independently. Next, to deter-
mine whether the activated form of STAT3 observed above can bind
to the Bcl-2 promoter, we looked for STAT3-binding sites in the Bcl-2
promoter region. We identiﬁed two putative STAT3-binding sites in
the Bcl-2 promoter (STAT3I: −1022 to −1002, STAT3Π: −791 to
−699). We determined whether STAT3 can directly bind to the Bcl-2
promoter by performing a chromatin immunoprecipitation assay. As
expected, the Bcl-2 genomic fragments captured by anti-STAT3 (Ser
727) were detected by PCR. Speciﬁcally, the binding of STAT3 to the
Bcl-2 promoter was increased by treatment with PA for 15 min
(Fig. 6F), suggesting that PA-induced STAT3 activation is essential
for binding to the Bcl-2 promoter and increasing Bcl-2 expression.
Furthermore, to investigate whether PLA2/Gi, RhoA, and Rac1 related
pathways are important for the binding of STAT3 to Bcl-2 promoter,
we examined the effects of PTX, RhoA or Rac1 siRNA transfection. As
shown in Fig. 6G, PTX completely abolished the binding of STAT3 to
the Bcl-2 promoter induced by PA. Also, knockdown of RhoA or Rac1in HeLa cells. HeLa cells were pretreated with 50 μM PD98059 and/or 50 μM SB203580
(for Bcl-2). Expression levels of ERK1/2, p-ERK1/2, p38 MAPK, p-p38MAPK and Bcl-2
NIH—http//rsb.info.nih.gov/ij/).
Fig. 6. Effects of PLD overexpression and PA on STAT3 phosphorylation in HeLa cells. (A) HeLa cells were infected with control retroviral vector and vectors harboring wtPLD1
and wtPLD2. At 72 h after infection, the cells were lysed. The amount of total STAT3 and phosphorylated STAT3 (Ser727) were determined by Western blot analysis. (B) Cells
were stimulated with PA (50 μM) for the indicated time periods, and the expression levels of STAT3 and p-STAT3 (Ser727) were determined by Western blot analysis. (C) Cells
were pretreated with mepacrine (50 μM) for 30 min and then stimulated with PA (50 μM) for 15 min. Expression levels of STAT3 and p-STAT3 (Ser727) were determined by
Western blot analysis. (D) Cells were pretreated with PTX (400 ng/ml) for 24 h and then stimulated with 10 μM LPA for 15 min (for p-STAT3) and 3 h (for Bcl-2). Expression levels
of STAT3, p-STAT3 (Ser 727), and Bcl-2 were determined byWestern blot analysis. (E) Cells were pretreatedwith 50 μMPD98059 and/or 50 μMSB203580 for 1 h and then stimulated
with 50 μM PA for 15 min (for p-STAT3) and 3 h (for Bcl-2) and expression level of STAT3, p-STAT3 (Ser727), and Bcl-2 were determined byWestern blot analysis. (F) Upper panel:
schematic representation of potential regulatory elements in the human Bcl-2 promoter. Lower panel: HeLa cells were treated with 50 μM PA for 15 min, and cells were collected for
CHIP assay using STAT3 (Ser727) antibody (see Section 2 for details. (G) Cells were pretreated with PTX (400 ng/ml) for 24 h. In case of knockdown study, cells were transiently
transfected with 100 nM RhoA or Rac1 siRNA for 48 h. In addition, cells were stimulated with 50 μM PA for 15 min and collected for CHIP assay using STAT3 (Ser727) antibody
(see Section 2 for details).
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by PA. Taken together, these data demonstrated that PLD plays an im-
portant role in STAT3 activation via the PLA2/Gi/ERK1/2, RhoA/ROCK/
p38 MAPK, and Rac1/p38 MAPK pathways.
3.6. Overexpression or knockdown of STAT3 regulates PA-induced
Bcl-2 expression
Finally, we investigated the effect of STAT3 activation on PA-induced
Bcl-2 expression in HeLa cells. HeLa cells were transiently transfected
with pMSCV-HA-STAT3-IRES-CL-EGFP or pMSCV-HA-IRES-CL-EGFP as
a control. As shown in Fig. 7A, overexpression of STAT3 by transient
transfection with pMSCV-HA-STAT3-IRES-CL EGFP led to more than a
two-fold increase in Bcl-2 expression in the absence of PA compared
to the controls. Furthermore, knockdown of STAT3 using STAT3 siRNAdecreased PA-induced Bcl-2 expression compared to control siRNA
(Fig. 7B), scramble siRNA was transfected as a control. These results
suggest that Bcl-2 expression is regulated by STAT3 transcriptional
activity in HeLa cells.
4. Discussion
PLD is a crucial enzyme providing defense against apoptosis in-
duced by various effectors including hydrogen-peroxide, glutamate
and Fas/CD95 agonist [43–46]. PLD expression and activity have been
implicated in the expression of anti-apoptotic proteins via a number
of signaling pathway. Recently, a close relationship between activation
of PLD and expression of Bcl-2 has been reported in stomach cells and
A20 cells [11,12]. However, the precise mechanism of Bcl-2 upregula-
tion by PLD remained unclear. In the present study, we showed that
Fig. 7. Role of STAT3 in PA-induced Bcl-2 expression in HeLa cells. (A) HeLa cells were transiently transfected with 5 μg of pMSCV-HA-IRES-CL-EGFP or pMSCV-HA-STAT3-IRES-CL-
EGFP as a control using lipofectamin 2000 reagent. At 48 h later the cells were treated with 50 μM PA for 15 min (for p-STAT3) and 3 h (for Bcl-2). STAT3, p-STAT3 (Ser727), and
Bcl-2 were assayed by Western blot analysis. (B) HeLa cells were transiently transfected with 100 nM STAT3 siRNA or scrambled siRNA as a control for 48 h and then stimulated
with 50 μM PA for 15 min (for p-STAT3) and 3 h (for Bcl-2). Expression levels of STAT3, p-STAT3 (Ser727), and Bcl-2 were determined by Western blot analysis and the intensity
of bands was quantiﬁed using Image J software (NIH—http//rsb.info.nih.gov/ij/).
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ment with exogenous PA, an enzymatic product of PLD, also increased
expression of Bcl-2. Together these results demonstrated that both
PLD isozymes and intracellular accumulation of PA are important for
regulating Bcl-2 expression.
In general, PLD is a key signaling molecule in cell physiology due to
generation of PA. PA is converted to DAG by PAP, and hydrolyzed to AA
and LPA by PLA2. In our data, propranolol had no effect on PA-induced
Bcl-2 expression, whereas mepacrine signiﬁcantly suppressed PA-
induced Bcl-2 expression, suggesting that PLA2, but not PAP, is involved
in the increased expression of Bcl-2 in HeLa cells. Consistent with this
observation, several studies have shown that PLD and PLA2 are involved
in increasing Bcl-2 expression via LPA synthesis [47–50]. To rule out in-
volvement of AA another PLA2 product, we treated cells with DPPA,
which has two palmitic acids instead of AA. We found that DPPA in-
creased the expression of Bcl-2, suggesting that LPA, not AA, is a key
molecule involved in Bcl-2 expression. LPA exerts diverse cellular ef-
fects by activating speciﬁc G protein-coupled receptors (GPCRs). Six
LPA-speciﬁc mammalian GPCRs, LPA 1–6, have been identiﬁed. LPA1–3
are members of the endothelial differentiation gene (EDG) family, the
other members, LPA 4–6, which are also similar to members of the Edg
family, were identiﬁed only recently and less is known about them
[51–56]. We have found that LPA2, LPA5, and LPA 6 are expressed in
HeLa cells, whereas LPA1, LPA3, and LPA4 are not detectible (data not
shown). G-proteins such as Gi/o, Gq/11, and G12/13 can be activated by
stimulated GPCRS [57,58]. Of these G-proteins, Gi/o protein is the most
promising candidate for mediating the activation of tyrosine kinases
and MAP kinases by LPA [59]. MAPKs including ERK1/2 and p38
MAPK are downstreammolecules of GPCR. Therefore, we tried to deter-
mine whether the ERK1/2 signaling pathway is involved in the PLD
mediated regulation of Bcl-2, and found that overexpression of PLD
isozymes or PA treatment increased phosphorylation of ERK1/2. To
this end, we found that mepacrine, PLA2 inhibitor, blocked PA-induced
ERK1/2 phosphorylation, and PTX, a Gi/o inhibitor, reduced both LPA-
induced ERK1/2 activation and Bcl-2 expression suggesting that PLD ac-
tivates ERK1/2 and induces Bcl-2 expression through a PLA2/Gi path-
way. However, PTX did not completely block the increase of Bcl-2
expression, which implies that there are other pathways for PLD medi-
ated Bcl-2 expression. Accordingly, we examined p38 MAPK as another
molecule downstream of GPCR. Phosphorylation of p38 MAPK was not
affected by mepacrine, even though it was activated by overexpressionof PLD isozymes and PA treatment, suggesting that it is not involved in
the PLA2/Gi pathway. Rho-related GTPases can regulate gene expression
by activating MAP kinase cascades [60], and Rho family proteins have
been shown to differentially affect different members of the Bcl-2
family. For examples, RhoA/ROCK suppresses the pro-apoptotic protein
Bax and enhances the anti-apoptotic proteins Bcl-2 and Bcl-xl, whereas
activation of the Rac1/Cdc42/PAK pathway inhibits pro-apoptotic pro-
teins including, Bax, Bim, and Bad, and stimulates Bcl-2 and Bcl-xl
expression [61–63]. In the present study, we found that PA stimulated
activation of Rac1 and RhoA and that inhibition of Rac1, RhoA or
the RhoA downstream effecter, ROCK, blocked both PA-induced p38
activation and Bcl-2 expression. This showed that PA-induced p38
MAPK activation was dependent on two pathways: RhoA/ROCK and
Rac1. Interestingly, we found that PA-induced Bcl-2 expression was not
completely blocked by either PD98059 or SB203580; however when
cells were treated with both inhibitors at same time, PA-induced Bcl-2
expression was completely blocked, indicating that PA-induced Bcl-2
expression is independently regulated by ERK1/2 and p38 MAPK,
respectively. Thus, we were able to conclude that the PLA2/Gi/ERK1/2,
RhoA/ROCK-/p38 MAPK and Rac1/p38 MAPK pathways all participate
in PA-induced Bcl-2 expression in HeLa cells.
In general, STAT3 is a cytoplasmic transcription factor that is in-
volved in cell growth, cell differentiation, cell survival, and the inﬂam-
matory response [64,65]. It is activated by the MAPK family including
ERK1/2, p38MAPK and SAPK/JNK in different cell lines [41,42] and,
activation of STAT3 regulates Bcl-2 expression [66,67]. We previously
showed that STAT3 phosphorylation regulates Bcl-2 expression in
response to ERK1/2 activation [68]. In the present study, we found
that overexpression of PLD isozymes or PA treatment increased
Ser727 phosphorylation of STAT3, but not its Tyr705 phosphorylation.
Pretreatment with mepacrine, PTX, PD98059 or SB203580 blocked
the phosphorylation of STAT3 (Ser727) and DN-RhoA and DN-Rac1
inhibited the PA-induced STAT3 (Ser727) phosphorylation (data not
shown).
Bcl-2 expression is regulated by several transcription factors,
including Sp-1, NF-кB, CREB, AP-1 and STAT3. Recent studies show
that activated STAT3 can bind directly to a sis inducible element in
the murine Mcl-1 promoter and increase Bcl-2 and Bcl-xL promoter
activity [69,70]. In the present study, we identiﬁed two functional
STAT3 binding sites in the Bcl-2 promoter region and found that
STAT3 (Ser727) upregulated Bcl-2 expression via direct interaction
Fig. 8. Proposed model for the signaling pathway of PLD-induced Bcl-2 expression
in HeLa cells. Our model suggests that PLD acts as an important signaling molecule to
increase the expression of Bcl-2 via STAT3 (Ser727) activation through PLA2/Gi/ERK1/
2, RhoA/ROCK/p38 MAPK, and Rac1/p38 MAPK pathways in HeLa cells.
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STAT3 knockdown using siRNA. However, another candidate, NF-кB,
was not interacted with the Bcl-2 promoter in the presence of PA
(data not shown). These results all indicate that PLD increases Bcl-2
expression by activating STAT3 (Ser 727) in HeLa cells.
In conclusion, our present study provides evidences that PLD is a
critical molecule in the activation of PLA2/Gi/ERK1/2, RhoA/ROCK/
p38 MAPK and Rac1/p38 MAPK pathways, respectively: These three
different pathways all appear to participate in the activation of
STAT3 (Ser727) resulting in increased expression of Bcl-2 in HeLa
cells (Fig. 8).
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